The business activities of Enzo Biochem are performed by the company’s three wholly owned subsidiaries . . . Enzo Life Sciences, Enzo Therapeutics and Enzo Clinical Labs. Such activities include research and development, manufacturing and marketing of biomedical research products and tools through Enzo Life Sciences and research and development of therapeutic products through Enzo Therapeutics and the operation of a regional clinical reference laboratory through Enzo Clinical Labs.
Enzo Biochem, Inc. reported improved sequential results for the first fiscal quarter ended October 31, 2010, the result of recent programs to reduce expenses, consolidate activities and expand operations.
The Company's financial condition remained strong, with working capital of $42.1 million. As of October 31, 2010, cash and cash equivalents, plus short term investments in US Treasury Bills, totaled $31.6 million. At November 30, 2010 Enzo’s cash, and cash equivalents and short-term investments were $33.9 million, which exceeded the July 31, 2010 balance by $0.3 million. Cash utilization in operations declined year over year by approximately $1 million to $1.8 million principally due to the reduced loss in the 2011 period. Management’s plan is to move towards being cash flow positive from operations in calendar 2011. There was no debt.
Enzo Biochem, Inc., is a growth-oriented integrated life sciences and biotechnology company focused on harnessing biological process to develop research tools, diagnostics and therapeutics, and serves as a provider of test services, including esoteric tests, to the medical community.
Power3 Medical Products, Inc. (OTC.BB:PWRM)
Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig's disease). Power3 applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 has developed a portfolio of products including BC-SeraPro™, a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials, and NuroPro®, a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer's, Parkinson's, and ALS diseases, for which it is currently engaged in Phase II clinical trials. These tests are designed to analyze an individual's proteins to detect the presence of disease, a patient's disease progression, a patient's response to a particular drug, and the mechanisms of disease present in the patient for optimal targeted therapy.
EMC Corporation (NYSE:EMC) announced the new Iomega® Personal Cloud technology, the ultimate data protection and remote access solution for small businesses and consumers that gives you the control of your own Personal Cloud without complexities and extra costs. Iomega's Personal Cloud is a revolutionary web-based computing architecture that connects your Iomega network storage device to other individuals and/or devices via the Internet. Unlike most public and private cloud applications, Iomega's Personal Cloud technology is completely self-owned – the content and accessibility is always under your control. Best of all, there are never any usage fees or subscription charges; instead, Iomega gives small businesses and consumers a great value for cloud access and protection.
EMC Corporation develops, delivers, and supports information infrastructure and virtual infrastructure technologies and solutions.
Corning Inc. (NYSE:GLW) announced that Corning Gorilla Glass has been designed into Acer’s ICONIA tablet computer. The ICONIA creates a distinctive tablet experience combining the versatility of a 14-inch form factor with a unique dual-screen layout and highly intuitive all-point touch functionality. The ICONIA’s design incorporates ultra-thin, durable Gorilla Glass as a cover glass for its dual multi-touch displays, and includes a full range of intuitive and easy-to-use features designed to fully utilize the devices’ multi-touch technology.
Corning Incorporated manufactures and processes specialty glass and ceramics products worldwide.
Weyerhaeuser Co. (NYSE:WY) will release fourth quarter 2010 results on Feb. 4 before the market opens. The company will hold a live conference call at 7 a.m. Pacific (10 a.m. Eastern) on Feb. 4 to discuss fourth quarter results. To access the conference call from within North America, dial 877-296-9413 (access code – 29868228) at least 15 minutes prior to the call. Those calling from outside North America should dial 1-706-679-2458 (access code – 29868228). Replays will be available for one week at 800-642-1687 (access code – 29868228) from within North America and at 1-706-645-9291 (access code – 29868228) from outside North America. The call is being webcast through Weyerhaeuser’
Weyerhaeuser Company grows and harvests trees, builds homes, and manufactures forest products worldwide.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/